|1.||Sun, Zheng: 2 articles (07/2008 - 07/2007)|
|2.||Hao, Aijun: 1 article (01/2013)|
|3.||Wong, Stephen T C: 1 article (01/2013)|
|4.||Jin, Guangxu: 1 article (01/2013)|
|5.||Wang, Lulu: 1 article (01/2013)|
|6.||Nie, Fang: 1 article (01/2013)|
|7.||Liu, Qian: 1 article (01/2013)|
|8.||Zhao, Hong: 1 article (01/2013)|
|9.||Yao, Linli: 1 article (01/2013)|
|10.||Cui, Kemi: 1 article (01/2013)|
08/01/2010 - "Furthermore, the marked sensitivity of BK5.erbB2 mice to the inhibitory effects of GW2974 during tumor promotion suggest greater efficacy for this compound when erbB2 is overexpressed or amplified as an early event in the carcinogenic process."
01/01/2013 - "This offers a new perspective on the role of GW2974 in tumor progression, providing a potential strategy for GBM treatment based on precise prescription."
08/01/2010 - "GW2974 effectively inhibited skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in wild-type and BK5.erbB2 mice, although a more marked effect was seen in BK5.erbB2 mice. "
07/01/2007 - "After GW2974 (4 mmol/L and 8 mmol/L) was applied topically, tumor incidence decreased from 80.0% (24/30) to 43.3% (13/30, P < 0.01) and 36.7% (11/30, P < 0.01) respectively, the average number of tumors decreased from 1.00 +/- 0.87 to 0.47 +/- 0.82 (P < 0.05) and 0.37 +/- 0.62 (P < 0.05), the average volume and burden of tumors also declined, tumor incidence decreased from 70.0% (21/30) to 40.0% (12/30, P < 0.05) and 33.3% (10/30, P < 0.01), the number of tumors declined from 1.83 +/- 1.91 to 0.67 +/- 0.99 (P < 0.05) and 0.43 +/- 0.68 (P < 0.01). "
01/01/2013 - "Similar results were observed in an intracranial GBM xenograft model, in which, although both doses of GW2974 slowed tumor growth, no improvement in survival was observed in mice treated with high-dose GW2974, presumably because of the augmentation of tumor invasion. "
|2.||Breast Neoplasms (Breast Cancer)
02/01/2007 - "A synergistic inhibitory effect was observed with the combination of inhibitors of EGFR-HER-2/neu (lapatinib or GW2974) and Bcl-2 (GX15-070 or HA14-1) on the growth of the MCF-7, MCF/18, and MTR-3 human breast cancer cell lines. "
08/01/2011 - "Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974). "
|3.||Prostatic Neoplasms (Prostate Cancer)
07/01/2010 - "We determined the effects of GW2974, a dual inhibitor of ErbB-1 and ErbB-2 tyrosine kinase activity, on growth, NSE, chromogranin A and osteopontin cytosol content in the androgen-independent prostate cancer cell line PC-3. "
07/01/2010 - "Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content."
|4.||Mouth Neoplasms (Oral Cancer)
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|8.||Epidermal Growth Factor Receptor (EGF Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)